Acadia Pharma (ACAD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $23.43 +0.30%
Revenue Growth %: +12.1%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- KKR reports over $900M in Q2 monetization income through June 24
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
